CZAR yields 1.56% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, CZAR + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CZAR + JNJ for your $10,000?
CZAR aims to mirror the performance of the Solactive Natural Monopoly Index, which includes global companies perceived to have a strong competitive edge within their sectors. The fund is focused on large- and mid-cap companies that meet certain requirements. This includes being part of a broader Solactive index aimed at Developed Markets, maintaining an average daily value traded, and meeting volume and free-float market capitalization percentage criteria. Stock selection for the fund is then based on fundamental financial metrics such as sales, profit margin, return on equity, inventory/total assets, and intangible assets/total assets. The top five firms within each sector are then chosen for the index. Weighting is designed to be sector-neutral, taking into consideration the free-float market capitalization of the index. Securities are then weighted equally within sectors, ensuring balanced exposure. CZAR is rebalanced seven business days after the semi-annual Selection Days in June and December.
Full CZAR Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.